All Columns articles
-
OpinionA unifying force for African medicines
The new African Medicines Agency is hugely important but faces significant challenges
-
OpinionWhat’s on your lab technology wish list?
Once-magical tools are now mundane. What will the next miracles be?
-
OpinionChanging the rules of global chemicals trade
Chemical dumping claims reflect US and China’s focus on national interests ahead of global markets
-
OpinionInhaler propellant switch is worth the effort
Memories of a year spent testing new inhaler valve designs
-
OpinionDon’t blame patients for the emissions of their inhalers
Alternatives with lower global warming potential are out there, but the onus can’t be on those suffering
-
OpinionA robotic helping hand
Mechanical labmates are making huge progress, but there are still big challenges to overcome
-
BusinessPfizer and Novo Nordisk’s battle over Metsera
Lawsuits fly in bidding war over developer of next generation weight loss drugs
-
OpinionSpin-out support is stretched thin
University entrepreneurs need more consistent help to bridge the gap betweeen ideas and businesses
-
OpinionA brief intro to altermagnetism
Experiments only directly confirmed the existence of this type of magnetic material last year but it’s already making waves
-
OpinionGoing round in circles over skills
Closing skills gaps in key professional groups requires collaboration between government, industry and educators
-
-
OpinionKeeping tabs on contamination
Argentina’s contaminated fentanyl tragedy highlights challenges of generic drug supply
-
OpinionTrump steps up pharma tariff threat
Taxing branded drug imports could hit biotech innovators hardest
-
OpinionSolar cell progress hinges on more than just materials
Solvents are a critical factor in the quest for more sustainable energy
-
OpinionDrowning in a sea of fakery
Addressing rising fraud in the scientific literature is a huge issue that AI is set to exacerbate
-
OpinionA global petrochemical shift
China’s rapid capacity expansion fuels global oversupply, leading plant closures in Europe and elsewhere
-
OpinionIs UK pharma really ‘uninvestable’?
Merck & Co, AstraZeneca (AZ) and Eli Lilly pulling UK projects highlights the precarious position of the country’s life sciences industry
-
OpinionUK biofuels burning out
With UK plants facing closure, what are the options and issues around different renewable fuels?
-
OpinionLiver toxicity remains an unpredictable hurdle for medicinal chemists
The liver’s complex role in metabolising drugs makes it both a critical consideration and potential stumbling block
-
OpinionDeadly fentanyl contamination exposes drug safety challenges
Bacterial contamination in medical fentanyl has killed at least 51 people in Argentina, highlighting pressures on generic drugmakers